spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

DuPont Achieves Non-GMO Certification for SeaGel®, Reinforces Commitment to Sustainable, Quality Ingredients

DuPont

DuPont Nutrition & Biosciences’ latest certification will allow manufacturers to add the iconic non-GMO Project verified seal to their end product, fostering brand transparency and consumer trust

WILMINGTON, Del., June 24, 2020 – Among consumers, the Non-GMO Project Verified seal is the most trusted non-GMO label, providing assurance that the product has completed a rigorous, unbiased evaluation for compliance with the Non-GMO Project Standard. Drug and dietary supplement manufacturers can now turn to DuPont Nutrition & Biosciences to bring that seal to their end-use soft capsule products.

After scrupulous testing of raw material sourcing and manufacturing, SeaGel® CAP101 and SeaGel® CAP203 non-animal soft capsule technologies achieved Non-GMO Project Verified certification, reinforcing DuPont’s commitment to providing safe, sustainable ingredients that meet industry demand.

SeaGel® offers a plant-based alternative to traditional soft capsules. While soft capsules are one of the most common delivery formats for active ingredients, they are traditionally made with gelatin. Naturally derived from seaweed, SeaGel® is animal-free, making it inclusive to vegan, vegetarian, Halal and Kosher diets. Its recent non-GMO designation allows manufacturers incorporating SeaGel® into their formulation to appeal to a wider range of consumers.

“As consumers become more informed about what goes into their daily supplements, they’re searching for products that are natural, sustainable and non-GMO,” said Michael Baumann, global strategic marketing manager, DuPont Nutrition & Biosciences. “Adding the iconic non-GMO butterfly to their end products helps manufacturers and brand owners provide customers with immediate assurance that a product aligns with their lifestyle needs.”

SeaGel® offers manufacturers solutions to a wide range of formulation challenges, and when compared to alternative vegetarian soft capsule technology, it provides superior sealing performance and reduced leakage. Since seaweed has a higher melting point than gelatin, SeaGel® soft capsules are more heat stable, ensuring they will not become sticky or melt together inside capsule bottles. Its adaptability to shape, color and coating—plus

easy incorporation into existing gelatin manufacturing operations—allows for a wide range of brand strategies with minimum capital investment.

“The dietary supplement market is growing rapidly, with 4,000 new products introduced each year in the U.S. alone,” said Benjamin Roscoe, application development & innovation manager, DuPont Nutrition & Biosciences. “By consistently evolving alongside our customers, we’re empowering them to differentiate from competitors and meet consumer demand with safe, natural and sustainably sourced ingredients.”

As North America’s only third-party non-GMO verification program, the Non-GMO Project’s verification continues to set the industry standard for non-GMO food, drug and beauty products. To achieve qualification, suppliers must first pass a rigorous product evaluation which includes a review of raw material sources, manufacturing practices and finished products to prevent contamination by genetically modified organisms (GMOs).

In achieving the recent certification, DuPont confirms its commitment to thorough and precise specifications, quality ingredients and sustainable practices, enabling manufacturers and brand owners to be transparent about ingredient sourcing and manufacturing processes. Ultimately this leads to increased consumer satisfaction and trust.

To learn more about SeaGel® and DuPont’s extensive product portfolio, please visit pharma.dupont.com/pharmaceutical-brands/seagel.html


About DuPont Nutrition & Biosciences
DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: www.dupontnutritionandbiosciences.com or www.biosciences.dupont.com

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at www.dupont.com.
web www.dupont.com/
 
Print this page
Send to a friend
   
spacer
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>


White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement